RESULTS SUMMARY

I. Results Related to Clinical Indication
- None detected by this exome sequencing test.

This result does not rule out the possibility that this patient has a variant that was not identified due to incomplete genomic coverage or limited knowledge of some genes or genetic conditions at this time.

II. Results Possibly Related to Clinical Indication
- None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

III. Incidental Findings Unlikely to be Related to Clinical Indication

A. Immediately Medically Actionable Disease-Causing Variants Not Related to Clinical Indication
- None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

B. Medically Actionable Childhood Onset Disease-Causing Variants Not Related to Clinical Indication
- None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

C. Medically Actionable Adult Onset Disease-Causing Variants Not Related to Clinical Indication
- None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

D. Carrier Status for Recessive Diseases Not Related to Clinical Indication
- None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

RECOMMENDATIONS

- Appropriate medical follow up is recommended for this patient’s history of sudden cardiac arrest.
- Genetic consultation is recommended. Consider additional testing (details below) for variants that possibly correlate with the patient’s phenotype and any incidental findings that the family intends to use for future medical decisions.
- General information about sequencing can be found in the Supplemental Information at the end of this report. Additional information regarding genes and genetic conditions is available at www.omim.org and www.genetests.org. Information for the family may be available at Genetics Home Reference (www.ghr.nlm.nih.gov).

LIMITATIONS

This test does not identify all genetic variants. We cannot exclude the possibility that this patient has additional disease-associated variants that were not identified or reported.
I. INTERPRETATION OF RESULTS RELATED TO CLINICAL INDICATION

A definite molecular cause for this patient’s symptoms was NOT identified. This result does not rule out the possibility that this patient has a variant that was not identified by this test. Limitations of the test are described in details on Page 4 of this report.

II. INTERPRETATION OF RESULTS POSSIBLY RELATED TO CLINICAL INDICATION

A molecular cause possibly related to this patient’s symptoms was NOT identified. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

III. INTERPRETATION OF INCIDENTAL FINDINGS UNLIKELY TO BE RELATED TO CLINICAL INDICATION

Incidental findings are divided into 4 categories:
- A) Immediately Medically Actionable - Results that suggest an immediate change in medical care, including screening or intervention, based purely on diagnosis (not symptoms) that may have a significant and permanent impact on morbidity or mortality.
- B) Medically Actionable Childhood Onset - Childhood onset results that could cause a serious health risk and have known options for improving health or remaining healthier through changes in treatment or management of a person’s health care.
- C) Medically Actionable Adult Onset - Adult onset results that could cause a serious health risk and have known options for improving health or remaining healthier through changes in treatment or management of a person's health care.
- D) Carrier Status for Recessive Disease - Carriers of a variant for an autosomal recessive disease do not generally have any symptoms, but they have a risk of having a child with a recessive disease if their partner is also a carrier of a pathogenic variant in the same gene. More information on the variants identified in this patient is described below, and in Table III D.

In this patient, a pathogenic variant was found in genes from the Carrier Status result category. This variant has been previously reported as pathogenic in variant databases and scientific literature. Variants of uncertain significance are not reported for incidental findings. If the personal or family history is strongly suggestive of a variant in a given gene/s, we would recommend gene-specific Sanger sequencing for the affected individual.

IIIA. Immediately Medically Actionable Disease-Causing Variants Not Related to Clinical Indication

None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

IIIB. Medically Actionable Childhood Onset Disease-Causing Variants Not Related to Clinical Indication

None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

IIIC. Medically Actionable Adult Onset Disease-Causing Variants Not Related to Clinical Indication

None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.

IIID. Carrier Status for Recessive Diseases Not Related to Clinical Indication

None detected. This result does not rule out the possibility that this patient has a variant that was not identified by this test.
Methodology
After extraction of genomic DNA, targeted exons were captured with the Agilent SureSelect XT Human All Exon V4 kit and were sequenced on the Illumina HiSeq 2000 platform with 100bp paired-end reads in the CHOP@BGI Sequencing Facility. The mitochondrial genome was not analyzed. Mapping and analysis were based on the human genome build UCSC hg19 reference sequence. Samples were sequenced at a minimum average coverage of 100x. All DNA variants associated with the clinical indication and reported here were confirmed via Sanger sequencing in the patient and the family members, when available. Variants of uncertain significance are only reported for genes related to the clinical phenotype. Variants related to traits, low risk for common disease, or untreatable adult onset degenerative diseases are not analyzed or reported. Common benign polymorphisms are also not reported.

Limitations
This test does not capture or analyze all regions of the exome/genome. Approximately 95% of the exome is captured consistently at 10x or greater. In addition, this test may not identify certain types of DNA variants, including large structural deletions/ duplications, triplet repeats or other repetitive DNA sequences, insertions or deletions >15 basepairs or variants in genes with associated pseudogenes. Lack of a definite disease-causing variant does not exclude the possibility that a patient may have a genetic variant that was not able to be identified by this test due to failure to capture or sequence that region of the genome. This analysis is based on current understanding of this test and of genetic disease. It is possible that the variant responsible for this patient’s condition was not identified or reported because it is not yet understood to be associated with disease based on current scientific knowledge.

Versions

<table>
<thead>
<tr>
<th>Human Reference Genome: hg19</th>
<th>1000 Genomes Phase 1 v3, Exome Variant Server 0.0.9, ExAC 0.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novalign 2.08.02</td>
<td>Picard 1.79</td>
</tr>
<tr>
<td>GATK 2.2-S</td>
<td>PediSeq Cardiac Genelist v2</td>
</tr>
</tbody>
</table>

The PediSeq Laboratory is a CLIA-compliant research laboratory. This test was performed as part of a research project. Therefore, results of this test should not be placed in the medical record or used to make medical decisions without first being confirmed in a CAP or CLIA-certified laboratory. For questions related to this analysis or results, please contact the PediSeq Laboratory at 267-426-8634 or biswass1@email.chop.edu. References and other information about this test can be found at http://www.research.chop.edu/programs/pediseq/.

Laura Conlin, PhD  
Laboratory Director

Ian Krantz, MD  
Medical Director
EXOME SEQUENCING

All the genetic material in a person is referred to as their genome. Whole genome sequencing attempts to look at the sequence of the entire DNA in a person’s body. The portion of the DNA that is needed to make proteins is referred to as the exome. The majority of genetic diseases for which we know the molecular cause result from variants in the exome. Exome sequencing only looks at the portion of DNA, about 1.5% of the total DNA that is used to make proteins.

Exome and genome sequencing cannot identify all of a person’s genetic variants because of the complexity of our genomes and the current limitations of test technology and knowledge. There are some areas of the exome or genome that will not be sequenced, partially due to the inability to capture all genes consistently and misalignment of DNA sequences with existing pseudogenes (copies of genes with a very similar sequence). In addition, exome sequencing is unable to identify certain types of genetic variants, particularly larger regions of missing or extra DNA (deletions/duplications), repeated sequences (including repeats associated with triplet repeat disorders, such as Fragile X syndrome and Huntington disease), and regions of the genome that are rearranged (structural rearrangements, such as inversions and translocations). Exome or genome sequencing may not identify the genetic basis of a patient’s condition, even if that person has a genetic condition. If results of exome or genome sequencing do not identify a causative variant, it is important to consider additional testing options.

INTERPRETING RESULTS OF EXOME/GENOME SEQUENCING

Interpreting results of exome and genome sequencing can be complex. There are several steps that may be helpful. These steps include:

Correlation with your patient’s symptoms
One of the most important steps in interpreting the results of exome or genome sequencing is to consider the meaning of the identified genetic variants in relation to the current symptoms and features of the patient, as well as the expected age of onset of the associated conditions. For example, if a child with hearing impairment has a pathogenic variant in a gene associated with hearing loss and onset of visual issues in adolescence, this variant may be relevant to the child’s future health, even if the child does not currently have any visual issues.

Determining if the mode of inheritance makes sense
In addition, it is important to consider the mode of inheritance of the genetic disorders associated with each gene or genetic variant. We have two copies of most of our genes. Autosomal dominant conditions are expressed when only one copy of a gene has a pathogenic variant, while autosomal recessive conditions are expressed when both copies of the gene have a pathogenic variant. For recessive diseases for which testing identified a single variant, it is important to consider the possibility that a second variant could have been missed due to lack of sequencing coverage. Many X-linked diseases are primarily expressed in boys, since males usually only have one copy of the X chromosome and females have two. Therefore, a female may carry a pathogenic variant in a gene on the X chromosome but have no symptoms of disease. Mitochondrial diseases can be inherited through recessive, dominant, or X-linked inheritance. In addition, mitochondrial diseases can be caused by pathogenic variants in the mitochondrial DNA. Mitochondrial DNA is located in the mitochondria and may not be tested through exome or genome sequencing of the nuclear DNA. Therefore, it is important to consider whether or not the mitochondrial DNA has been tested in patients in whom you suspect a mitochondrial disease.

Verifying that genes relevant to the patient’s condition were tested
As described above, exome and genome sequencing may not test all areas of the genome and may not test certain genes consistently. Therefore, if you know of certain genes that you feel are highly likely to be associated with your patient’s symptoms, it is important to verify that the testing covered these genes and to consider additional testing of these genes. It is particularly important to remember that exome and genome sequencing may not identify large deletions or duplications.

GENETIC CONSULTATION

Genetic consultation is the process of evaluating the genetic etiology of a patient’s condition and providing recommendations for additional testing and future medical management. Board-certified MD or PhD geneticists, genetic counselors, or specialists often provide genetic consultations with expertise in the genetics of a specific type of disorder. A directory of board-certified geneticists can be found at www.acmg.net and a directory of genetic counselors can be found at www.nsgc.org.
**TERMINOLOGY**

**Coverage** refers to the *average* depth or the average number of times the DNA was sequenced over a specific region of the exome/genome or over the entire exome/genome OR the average percentage of a given gene, region, exome or genome that was sequenced.

**Depth** refers to the number of times a specific nucleotide/base (location in the DNA) is sequenced. The more times the variant is sequenced, the greater the depth, and the more likely that the result is accurate.

**Exon** refers to the segments of a gene that are “expressed” or made into RNA and proteins. During the production of a protein, the exons of a gene are spliced and put together.

**Intron** refers to the segments of a gene that are NOT “expressed” and NOT made into RNA and proteins. During the production of a protein, the introns of a gene are spliced out and discarded while the exons are put together to produce the protein. Introns help regulate splicing and gene expression.

**Variant** is often used to refer specifically to genetic variants that are associated with disease. However, a variant is actually any variant or change in the sequence of DNA that differs from the standard sequence.

**MLPA** (Multiplex Ligation-dependent Probe Amplification) is often used to rapidly look at genomic DNA for copy number changes (deletions and duplications) of small to moderate size. For this method, probes are matched to DNA and amplified. The amounts of amplified products are then compared to a reference to determine how many copies of each DNA segment are present.

**Sanger Sequencing** is the “gold standard” of genetic testing used to sequence a single gene, a specific region of a gene, or a small number of genes. Because exome and whole genome sequencing are new technologies, Sanger sequencing is often used to verify the presence of specific variants in a person’s genes.

**SNP** - a single nucleotide polymorphism, is a change of one nucleotide for a different nucleotide in DNA.

**SNP Array** looks at a large number of SNPs that are common in the general population. The presence or absence of these SNPs can identify missing segments or additional copies of regions in the genome. Some of these large changes cause disease, while others do not.

**Variant** refers to a change or variation in the DNA sequence that differs from the standard reference sequence.

**Variants of Uncertain Significance (VUSs)** are genetic changes that are not fully understood. These variants either do not have a definite association with disease, not understood enough to be deemed benign or there is limited information to make a clear judgment. More information gathered in the future, such as a report of the VUS in another patient or in a control population, may help determine whether or not these VUSs are truly associated with disease.

**Likely Pathogenic Variant** is a variant that shows some evidence that it is associated with disease, but the evidence may not be well understood at the current time, or only a few reports of evidence have been published in the literature. More information gathered in the future may confirm that this variant is definitely associated with disease.

**Pathogenic Variant** is a variant that has published evidence that it is associated with disease. In some cases, the exact variant has not been previously identified in the literature; however, there is abundant evidence that the disease is associated with a certain type of variant that results in the loss of the protein product from that allele (loss of function). **Heterozygous** refers to a genetic variant or change that is only found in one copy of a person’s gene and is not found in the second copy.

**Homozygous** refers to a genetic variant or change that is in both copies of a person’s gene.

**Hemizygous** refers to a genetic variant or change that is found in a gene on the X chromosome of a male. Because males only have one copy of the genes on the X chromosome, males are considered hemizygous for these variants instead of heterozygous or homozygous.

**ANALYSIS DETAILS**

**OMIM** (Online Mendelian Inheritance in Man) is an online database that details what is currently known about the majority of genes and genetic conditions.

**EVS** (Exome Variant Server) contains data about variants identified through the NHGRI GO Exome Sequencing Project (ESP). This server can be used to filter variants based on their frequency. For more information, visit [http://evs.gs.washington.edu/EVS/](http://evs.gs.washington.edu/EVS/)

**1000 Genomes** is a catalog of sequence data from over 1000 genomes. Like EVS, this data can be used to filter variants based on their frequency. For more information, visit [http://www.1000genomes.org/](http://www.1000genomes.org/)

**ExAC** (Exome Aggregation Consortium) is a data set provided on 60,706 unrelated individuals sequenced as part of genetic studies, including data from EVS and 1000 Genomes, that can be used to filter variants based on their frequency. For more information, visit [http://exac.broadinstitute.org/](http://exac.broadinstitute.org/)